Development of Treatment for Severe Malaria

This project aims to develop a novel, non-artemisinin combination therapy that addresses the concerns of emerging artemisinin partial resistance and the clinical observation of delayed parasite clearance. It also seeks to prevent the misuse of artesunate monotherapy for treating acute uncomplicated malaria. The project’s specific objectives include the development of delivery method formulations, non-clinical tolerability studies, stability studies, and a phase I first-in-human clinical study. This new combination therapy aims to improve upon existing artesunate options by offering enhanced ease of use, efficacy, and cost-effectiveness. The development of this novel treatment for severe malaria responds to the urgent global health need for new therapeutic options in the face of growing resistance to artemisinin-based combination therapies (ACT), which are currently WHO’s recommended treatment for uncomplicated Plasmodium falciparum malaria.